The present treatment of advanced and metastatic medullary thyroid carcinoma (MTC) is unsatisfactory. Tissue-specific cancer gene therapy is a novel alternative approach. We developed a recombinant adenovirus expressing Herpes simplex type 1 thymidine kinase (HSVtk) driven by a modified CALC-I promoter TCP (AdTCPtk). Infection with this virus showed efficient cytotoxic effect on MTC cell lines (rMTC and TT cells) after treatment with ganciclovir (GCV) in vitro. In a syngenic WAG/Rij rat model, the combination of AdTCPtk/GCV treatment with administration of murine interleukin-12 (mIL-12) expressing adenovirus under control of TCP (AdTCPmIL-12) resulted in effective growth suppression of tumor at the treated site and also at a distant untreated site, in comparison to treatment with AdTCPtk/GCV or AdTCPmIL-12 alone. Moreover, intravenous injection of AdTCPtk, or AdTCPtk+AdTCPmIL-12, followed by administration of GCV, did not cause evident toxicity after administration of GCV. These results indicate that this combined system can provide an effective therapy for metastatic MTC with minimal toxicity.
M edullary thyroid carcinoma (MTC), a calcitoninproducing neoplasm derived from thyroid C cells, is responsible for about 5% of thyroid tumors. 1 At present, surgery is the only curative treatment for this disease. Metastases are commonly present at the time of operation, leading to death in 50% of patients. At present, there are no satisfactory approaches for the treatment of advanced metastatic MTC.
Replication-defective adenovirus-mediated gene therapy is a promising approach in a variety of cancers including endocrine cancers. 2 One of the most useful tools is the Herpes simplex type 1 thymidine kinase (HSVtk)/ prodrug ganciclovir (GCV) system. 3 GCV is first converted to the monophosphate form in HSVtk-transduced tumor cells, and then endogenous thymidine kinases generate GCV triphosphate, which induces cytotoxicity of tumor cells, resulting in apoptotic or nonapoptotic cell death. 4 Moreover, cells not transduced by HSVtk can also show cytotoxicity because of a bystander effect, which is dependent on gap-junctional intracellular communication. [5] [6] [7] A second approach utilizes expression of the cytokine interleukin 12 (IL-12), which stimulates NK and NKT cells and initiates a Th1-type immune responses by activation of CD4 + and CD8 + cells. IL-12 is also a strong inducer of IFN-g, mainly from antigen-presenting cells (APCs) or T cells. Induction of IFN-g is crucial for antitumor activity partly due to antiangiogenesis and acquisition of antitumor immunity. 8, 9 Combined gene therapy using HSVtk/GCV and IL-12, usually driven by the CMV promoter, has induced more enhanced antitumor activity than either alone. [10] [11] [12] [13] [14] [15] A disadvantage of this strategy is its toxicity to noncancerous tissues such as the liver. Intratumoral injection of adenoviral vectors can be followed by systemic vector leakage to nontarget organs. 16 This may make related toxicity serious, especially in liver. 17, 18 A system using a tissue-specific promoter is more advantageous, and useful to prevent toxicity. 19, 20 We reported that expression of HSVtk under control of the whole CALC-I promoter showed cytotoxicity in MTC cells after treatment with GCV. 21 Further, we developed an adenovirusinducing tumor-specific expression of murine IL-12 (mIL-12) driven by a modified CALC-I promoter (AdTCPmIL-12), and demonstrated that treatment with this adenovirus resulted in regression of rat MTC tumors in syngenic WAG/Rij rats, without significant toxicity. 22 In this study, we have developed a new recombinantadenovirus-expressing HSVtk under the control of a modified CALC-I promoter (AdTCPtk). We demonstrate that in vitro treatment with this adenoviral vector and GCV results in cytotoxicity of MTC cells. In vivo treatment of rMTC tumors in Wag/Rij rats with AdTCPtk/GCV and AdTCPmIL-12 shows more antitumor effects in comparison to use of AdTCPtk/GCV or AdTCPmIL-12 alone, and is without evidence of toxicity. This combined gene therapy can provide more effective and less toxic treatment of MTC.
Results

Construction of adenovirus-expressing HSVtk
A DNA fragment containing HSVtk and bovine growth hormone poly A (pA) was obtained by digestion of pBStk with BamHI and HindIII. pDTCPmIL-12 was digested with EcoRI, and blunt-ended. We obtained the shuttle plasmid pDTCPtk by inserting the HSVtk+pA piece into pDTCPmIL-12 (Fig 1a) . Recombinant adenovirus was generated by cotransfection of this shuttle plasmid with pJM17 into 293 cells. We identified the correct virus by detection of a 2500 bp band, including HSVtk, after digestion with SalI (Fig 1b) . A fragment of HSVtk (393 bp), derived from mRNA of AdTCPtk-infected rMTC cells, was detected by RT-PCR analysis (Fig 1c) . We also detected this fragment in rMTC tumors treated with HSVtk-expressing viruses in vivo (Fig 1d) .
Characterization of AdTCPtk in vitro
To evaluate MTC cell-specific cytotoxicity of AdTCPtk/ GCV, two MTC cell lines (rMTC and TT) and four non-MTC cell lines (HeLa, C6, HepG2 and Cos1) were treated with viruses at indicated MOI and GCV at various concentrations. AdTCPtk-infected rMTC cells showed high sensitivity to GCV in both GCV-dose-and virus-dose-dependent manner. The IC 50 was 45.7 mM of GCV at 30 MOI and less than 0.1 mM at 100 MOI. Treatment with AdTCPtk and GCV also killed TT cells, with IC 50 s at 30 and 100 MOI of 2.2 and 3.1 mM. There was no decrease of cell viability after infection with mock or AdTCPluc, a luciferase-expressing vector driven by TCP, in either cell line. However, in non-MTC cell lines, we also found significant cell killing effects after treatment with AdTCPtk/GCV (Fig 2) . These results indicate that treatment with AdTCPtk/GCV shows efficient cytotoxic effect on both MTC cell lines, but does not maintain cell specificity in these in vitro studies with tumor cell lines. We have previously observed that expression of a ''cell-specific'' promoter is less rigidly controlled in in vitro in tumor cell lines than in in vivo studies in animals. ) were infected with AdTCPtk at the indicated MOIs. Total RNA was extracted 48 hours later. Total RNA (1 mg) was reverse-transcribed, followed by DNase I treatment, and amplified for 40 cycles. The PCR products were visualized in a 0.5 mg/ml ethidium-bromide 2% agarose gel. The expected band size is 393 bp for HSVtk and 763 bp for b-actin. P, positive control for PCR using 10 ng of plasmid pBStk; N, negative control for PCR without DNA. (d) Expression of HSVtk in infected rMTC tumor in vivo. A pre-established rMTC tumor was infected with 2 Â 10 9 PFU of mock, AdTCPluc, AdCMVtk or AdTCPtk. Tumor was harvested 48 hours after infection, then a portion was homogenized and total RNA was extracted. Total RNA (1 mg) was reverse-transcribed, followed by DNaseI treatment, and amplified for 40 cycles. The PCR products were visualized in a 0.5 mg/ml ethidium-bromide 2% agarose gel. P, positive control for PCR using 10 ng of plasmid pBStk; N, negative control for PCR without DNA.
In vivo antitumor effect on rMTC tumor after treatment with AdTCPtk/GCV alone or in combination with AdTCPmIL-12
Next, we evaluated the antitumor activity of AdTCPtk/ GCV treatment alone, or combined with AdTCPmIL-12, in vivo. Two tumors were developed and one of two tumors was treated with the virus. The growth of both tumors was monitored. The tumor growth was decreased at the site treated with AdTCPtk or AdCMVtk, but we did not find any antitumor effects on the untreated tumor. AdTCPmIL-12 also decreased tumor growth at the treated site, less so at the untreated site. AdTCPtk/ GCV+AdTCPmIL-12 suppressed tumor growth more than other groups at both sites (Fig 3) . These results indicate that both AdTCPtk/GCV and/or In vitro assays demonstrated that AdTCPtk/GCV was also cytotoxic in non-MTC cell lines. To estimate in vivo toxicity of AdTCPtk/GCV alone or in combination with AdTCPmIL-12, the viruses were injected into rats intravenously, and GCV was administered for 5 days.
We investigated gain of body weight, weight of spleen, liver transaminases in blood and histological changes. The rats given AdCMVtk/GCV alone displayed loss of body weight, but this was not seen in other groups including animals treated with AdTCPtk/GCV alone or in combination with AdTCPmIL-12 (Fig 4a) . Neither AdTCPtk/ GCV nor AdTCPtk/GCV+AdTCPmIL-12 resulted in an increase or reduction of splenic weight, whereas spleens from animals treated with AdCMVtk/GCV were slightly atrophic (Fig 4b) . Treatment with AdCMVtk/GCV caused high levels of serum GOT and GPT, but there was minimal increase of these enzymes in the groups given AdTCPtk/GCV or AdTCPtk/GCV+AdTCPmIL-12 (Fig 4c) . AdCMVtk/GCV-treated livers were yellowish, 
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and microscopically showed striking accumulation of lymphocytes and neutrophils in the triads, swollen hepatocytes with ballooned nuclei and vacuolation of cytoplasm and single cell death of hepatocytes. In contrast, AdTCPtk/GCV-and/or AdTCPmIL-12-treated livers had no macroscopic changes. There was occasional accumulation of lymphocytes in the area of portal vessels in all animals including AdTCPluc-treated animals (Fig  4d) . Spleens from animals treated with AdCMVtk/GCV had diminished white pulps and histiocytes were increased, but this was not seen in spleens from animals treated with AdTCPtk/GCV and/or AdTCPmIL-12. Histological abnormalities were not recognized in the kidney, lung or thyroid in any group (data not shown). We did not find abnormal behavior, suggestive of neuropathologic effect, in any groups.
These results indicate that in vivo treatment with AdTCPtk/GCV or its combination with AdTCPmIL-12 does not cause toxicity, and that AdTCPtk maintains tissue specificity in vivo in contrast to lack of specificity in vitro.
Discussion
Our aim is the establishment of more effective and less toxic gene therapy of MTC. We have already developed adenovirus-mediated gene therapy for MTC using HSVtk/GCV or IL-12. 23 In this work, we generated an HSVtk-expressing adenovirus under the control of a modified CALC-I promoter TCP (AdTCPtk), and investigated antitumor activity and toxicity of AdTCPtk/GCV alone or in combination with AdTCPmIL-12. The TCP was constructed from two tandemly arranged tissue-specific enhancer elements (TSEs), and a minimal proximal CALC-I promoter, including exon 1 of the CALC-I gene. The TSE is a DNA sequence located approximately 1 kb upstream from the transcription start site of CALC-I gene, and includes an Ets-like response element and a CANNTG Ebox motif that are related to cell-specific transcription of CALC-I gene. 24 Messina et al 25 reported that the TCP promoter induced greater luciferase expression than did the full-length natural promoter in TT cells, and had little activity in non-MTC cells by transfection assay. We already reported that AdTCPluc induced high luciferase expression in both rMTC and TT cells, but little in other cells such as Cos1, HeLa, C6, HepG2 and T98G (human glioblastoma cell line). 22 AdTCPtk/GCV produced strong cytotoxicity in both MTC cell lines in vitro. However, its cell-specific cytotoxicity was not maintained, because AdTCPtk/ 
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GCV also killed non-MTC cell lines including HeLa, C6, HepG2 and Cos1. The exact reason for this is uncertain, but may be related to the fact that these are cancer cell lines, not normal cells. Some expression of calcitonin or calcitonin gene-related peptide (CGRP), encoded by CALC-I gene, is seen in various tissue such as liver, lung, kidney and brain. 26, 27 Thus, the CALC-I promoter may have activity in these cells. CALC-I promoter is also activated in HeLa and Cos1 cells as described previously. However, in vivo, we did not find toxicity in any tissues including liver after treatment with AdTCPtk/GCV or AdTCPtk/GCV+AdTCPmIL-12 in contrast to AdCMVtk/GCV. This fact means that the activity of CALC-I promoter is strictly regulated in vivo, and that cytotoxicity due to AdTCPtk/GCV in vitro is not necessarily related to its toxicity in vivo. A variety of other factors may affect cytotoxicity of the HSVtk/GCV system. Elshami et al 28 reported that elevation of HSVtk enzyme levels per cell above a minimal level would not augment HSVtk/GCV cytotoxicity. Both Beck et al 29 and Maron et al 30 have pointed out that HSVtk/GCVmediated cell death effect is variable in different cells. These findings may indicate that some cells are very susceptible even to a small amount of GCV triphosphates, and that susceptibility is different between tumor cells and nontumor cells, derived from the same tissue.
In our tumor treatment study, AdTCPtk/GCV or AdCMVtk/GCV alone showed antitumor activity. The combination of AdTCPtk/GCV with AdTCPmIL-12 tended to show strong antitumor effects on both treated and untreated tumor. We believe that release of tumor antigen by AdTCPtk/GCV may enhance the antitumor effect of IL-12 produced by AdTCPmIL-12. It is reported that killing tumor cells in vivo with the HSVtk/GCV system generates some antitumor immunity, determined in part by nonapoptotic cell death and by the levels of inducible heat-shock protein (hsp) expression, such as hsp70, induced during the process of cell death. 31 Tumor-cell-killing-induced hsp70 expression initiates production of Th1 cytokines such as IFN-g, TNF-a and IL-12 that enhance immunogenicity via a T-cell-mediated mechanism and targets immature dendric cell precursors to enhance antigen uptake. Hsp70 also promotes the maturation of dendric cells. 32, 33 We are not sure whether our system induces apoptosis in treated rMTC tumors, although Soler et al 34 have reported that apoptotic cell death occurred in a GCV-treated rMTC tumor generated by retrovirus-mediated HSVtk genetransduced rMTC cells. Since apoptotic cells do not trigger inflammatory immune response, 35 release of more tumor antigen and hsp from nonapoptotic cell death may be important for enhancement of antitumor effects in our system.
In conclusion, our data confirm that combination therapy using AdTCPtk/GCV and AdTCPmIL-12 induces strong antitumor effects on rMTC tumors in comparison to treatment with AdTCPtk/GCV or AdTCPmIL-12 alone and does not induce toxicity. This combined system can provide a more effective and less toxic therapy for MTC.
Materials and methods
Cell culture and animal
Rat MTC cell line (clone 6-23) was purchased from American Type Culture Collection (ATCC) and cultured in DMEM containing 15% horse serum. TT (human MTC cell line) was also purchased from ATCC and maintained in RPMI1640 with 15% fetal bovine serum (FBS). HeLa (human cervical carcinoma cell line), HepG2 (human hepatocellular carcinoma cell line), C6 (rat glioma cell line) and Cos1 (monkey kidney cell line) were cultured in DMEM with 10% FBS. The 293 cells (human embryo kidney cell line) were grown in MEM with 10% calf serum. All media were supplemented with lglutamine, 100 U/ml penicillin and 100 mg/ml streptomycin. Culture was performed at 371C in a humidified atmosphere at 5% CO 2 . All culture reagents were purchased from Mediatech Inc (Herndon, VA) or Invitrogen (Gaithersburg, MD).
WAG/Rij rats were bred at the Carlson Biocontainment Suit under standard conditions based on the Guidelines of the Animal Resource Center.
Recombinant adenoviruses
The plasmid pDE1sp1B were purchase from Microbix Biosystems Inc.
(Ontario, Canada, M8Z3A8). p(TSE)2CP 1 .GL3 is a plasmid containing TCP, which consists of two tandemly arranged TSEs upstream of a PCR product encompassing nucleotides -128 to +104 of the human CALC-I promoter. This plasmid was a kind gift of Dr Bruce G Robinson (University of Sydney). The plasmid pBStk, containing HSVtk gene, was kindly provided by Dr SLC Woo (Baylor College of Medicine). Adenoviral backbone vector pJM17 was also kindly provided by Dr S Refetoff (The University of Chicago).
The detailed method for construction of AdTCPtk is described in Results.
AdTCPluc, AdCMVtk and AdTCPmIL-12 were constructed as previously described. 21, 22 Recombinant adenovirus was generated by cotransfection of the shuttle plasmid with pJM17 into 293 cells using the calcium phosphate precipitation method, and rescued and propagated in 293 cells. Virus was purified by double cesium chloride gradient ultracentrifugation. Viral titer was determined by plaque assay using 293 cells. Purified virus was stored with 10% glycerol at À851C for further use.
Generation of rMTC tumor
Rat MTC cells were washed and resuspended in serumfree medium. Cells (1.5 Â 10 6 ) were injected subcutaneously into 5-7-week old WAG/Rij rats. Palpable tumors usually developed within 5-8 days.
Detection of HSVtk mRNA in virus-infected rMTC cells and rMTC tumors rMTC cells (1 Â 10 6 ) were infected in vitro with virus at MOI of 0-300 for 1 hour, and then incubated for 48 hours Combined gene therapy of MTC with HSVtk/GCV and IL-12 M Yamazaki et al in six-well plates. In total, 2 Â 10 9 PFU of virus was injected into rMTC tumor in vivo and then tumors were harvested 2 days later. Total RNA was isolated with TRI Reagent (Molecular Research Center, Inc, Cincinnati, OH) and treated with DNase I (Invitrogen cooperation). RNA (1 mg) was used for cDNA synthesis using SuperScriptt First Strand Synthesis System for RT-PCR (Invitrogen cooperation). cDNA mixture (1 ml) was subjected to PCR by using 30-40 cycles comprising 60 seconds of denaturation at 941C, 60 seconds of annealing at 541C and 60 seconds of extension at 721C. b-Actin was detected as positive control by using specific oligonucleotide primers. 36 The primers for HSVtk were the following: 5 0 -CGATACCTTATGGGCAGCAT-3 0 (sense); 5 0 -GT-TATACAGGTCGCCGTTGG-3 0 (antisense).
Cytotoxic assay in vitro
Rat MTC cells (1 Â 10 3 /well), TT cells (1 Â 10
